Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen Receives $300K Investment, Seeks Additional Funds to Qualify for NSF Matching Grant

NEW YORK, Jan. 20 (GenomeWeb News) - Lucigen of Middleton, Wis., has received $300,000 in initial funding from undisclosed investors, the company said today.


Lucigen said it is seeking an additional $200,000 in equity financing in order to qualify for a matching grant from the National Science Foundation that would bring its total funding to $1 million.


The company plans to use the funds to expand the manufacturing and marketing capabilities for its gene cloning products and its proprietary Single Cell Genomics technology, which it uses to discover new, commercially valuable enzymes in extremophiles.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.